<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pain Res</journal-id><journal-id journal-id-type="iso-abbrev">J Pain Res</journal-id><journal-id journal-id-type="publisher-id">Journal of Pain Research</journal-id><journal-title-group><journal-title>Journal of Pain Research</journal-title></journal-title-group><issn pub-type="epub">1178-7090</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6174683</article-id><article-id pub-id-type="doi">10.2147/JPR.S172235</article-id><article-id pub-id-type="publisher-id">jpr-11-2123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Intraoperative use of methadone improves control of postoperative pain in morbidly obese patients: a randomized controlled study </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Machado</surname><given-names>Felipe Chiodini</given-names></name><xref ref-type="aff" rid="af1-jpr-11-2123"/><xref ref-type="corresp" rid="c1-jpr-11-2123"/></contrib><contrib contrib-type="author"><name><surname>Palmeira</surname><given-names>Claudia Carneiro de Araújo</given-names></name><xref ref-type="aff" rid="af1-jpr-11-2123"/></contrib><contrib contrib-type="author"><name><surname>Torres</surname><given-names>João Nathanael Lima</given-names></name><xref ref-type="aff" rid="af1-jpr-11-2123"/></contrib><contrib contrib-type="author"><name><surname>Vieira</surname><given-names>Joaquim Edson</given-names></name><xref ref-type="aff" rid="af1-jpr-11-2123"/></contrib><contrib contrib-type="author"><name><surname>Ashmawi</surname><given-names>Hazem Adel</given-names></name><xref ref-type="aff" rid="af1-jpr-11-2123"/></contrib></contrib-group><aff id="af1-jpr-11-2123">Anesthesiology Department, hcFMUsP, Universidade de São Paulo, São Paulo, Brazil, <email>felipe.chiodini@hotmail.com</email></aff><author-notes><corresp id="c1-jpr-11-2123">Correspondence: Felipe Chiodini Machado, Universidade de São Paulo, HCFMUSP, Anesthesiology Department, Rua Oscar Freire, 2040, ap. 56, São Paulo 05409-011, Brazil, Tel +55 1199 943 2343, Fax +55 112 661 7947, Email <email>felipe.chiodini@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2018</year></pub-date><volume>11</volume><fpage>2123</fpage><lpage>2129</lpage><permissions><copyright-statement>© 2018 Machado et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title><text><SENT sid="1" pm="."><plain>Objectives </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Surgical patients still commonly experience postoperative pain. </plain></SENT>
<SENT sid="3" pm="."><plain>With the increasing prevalence of obesity, there is a growing demand for surgical procedures by this population. </plain></SENT>
<SENT sid="4" pm="."><plain>Intraoperative use of methadone has not been well assessed in this population. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="5" pm="."><plain>Materials and methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Patients with a body mass index of 35 kg/m2 or more undergoing bariatric surgery were randomly assigned to receive either fentanyl (group F) or methadone (group M) in anesthesia induction and maintenance. </plain></SENT>
<SENT sid="7" pm="."><plain>The primary outcome was morphine consumption during the first 24 hours after surgery through a patient-controlled analgesia device. </plain></SENT>
<SENT sid="8" pm="."><plain>Secondary outcomes were pain scores at rest and while coughing, opioid related side effects, and patient satisfaction. </plain></SENT>
<SENT sid="9" pm="."><plain>The patients were also evaluated 3 months after surgery for the presence of pain, dysesthesia, or paresthesia at surgical site. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>Postoperative morphine consumption was significantly higher for patients receiving fentanyl than methadone during the postoperative period at 2 hours (mean difference [MD] 6.4 mg; 95% CI 3.1–9.6; P&lt;0.001), 2–6 hours (MD 11.4 mg; 95% CI 6.5–16.2; P&lt;0.001), 6–24 hours (MD 10.4 mg; 95% CI 5.0–15.7; P&lt;0.001), and 24–48 hours (MD 14.5 mg; 95% CI 3.9–25.1; P=0.01). </plain></SENT>
<SENT sid="12" pm="."><plain>Patients from group F had higher pain scores until 24 hours postoperatively, higher incidence of nausea and vomiting, lower satisfaction, and more evoked pain at surgical scar at the 3-month postoperative evaluation than group M. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>Intraoperative methadone can safely lower postoperative opioid consumption and improve postoperative pain scores compared with fentanyl in morbidly obese patients. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><title>Keywords</title><kwd>postoperative pain</kwd><kwd>bariatric surgery</kwd><kwd>acute pain</kwd><kwd>postoperative pain</kwd><kwd>methadone</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="15" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>Despite recent developments in postoperative pain management, many patients still suffer from moderate-to-severe pain after surgery. </plain></SENT>
<SENT sid="17" pm="."><plain>It is estimated that postoperative severe pain occurs in 20%–40% of all surgical procedures.1 Pain during the first days after surgery might lead to severe complications, such as delayed ambulation, increased incidence of cardiovascular and pulmonary complications with increased morbidity and mortality, and the development of chronic postoperative pain.1–6 Therefore, the proper treatment of postoperative pain is of great importance, especially in procedures that lead to severe pain. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>The prevalence of morbid obesity is increasing in most countries, and there is a growing demand for surgical procedures in these patients (both related and not related to obesity). </plain></SENT>
<SENT sid="19" pm="."><plain>The postoperative pain management in these patients is especially important, considering this population has greater susceptibility to cardiovascular, pulmonary, and thromboembolic complications in the perioperative period.7–9 </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Methadone is a strong µ-opioid receptor (MOR) agonist. </plain></SENT>
<SENT sid="21" pm="."><plain>It antagonizes glutamate by blocking the N-methyl-d-aspartate receptor (NMDAr) and inhibits the reuptake of serotonin and noradrenaline in the central nervous system. </plain></SENT>
<SENT sid="22" pm="."><plain>When used parenteral, its latency is of 10–20 minutes, with 4–36 hours of action, depending on the dosage, due to its long half-life and the large individual variation.10,11 When administered in doses of 20–30 mg, analgesia generated by intravenous (i.v.) methadone can last from 24 to 36 hours.12 </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Methadone may be an interesting option in the treatment of postoperative pain, and the dose used in anesthesia may contribute to immediate postoperative analgesia, when the highest pain scores are usually reported. </plain></SENT>
<SENT sid="24" pm="."><plain>Few published studies have compared intraoperative methadone to fentanyl or sufentanil in cardiac surgery,13,14 spine surgery,15 laparoscopy,16 hysterectomy,17,18 abdominal surgery,18,19 and major surgery in children.20 To our knowledge, no study has compared the use of intraoperative methadone with other opioids for the morbidly obese patients. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>The present study was designed to evaluate the efficacy and safety of intraoperative i.v. methadone in reducing postoperative pain and opioid consumption in morbidly obese patients submitted to open bariatric surgery. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods"><title><text><SENT sid="26" pm="."><plain>Materials and methods </plain></SENT>
</text></title><p><text><SENT sid="27" pm="."><plain>This study was approved by the University of São Paulo Institutional Review Board (identifier 1.412.317) and written informed consent was obtained from all subjects participating in the trial. </plain></SENT>
<SENT sid="28" pm="."><plain>The trial was registered prior to patient enrollment at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT02775474, principal investigator: FCM, date of registration: May 17, 2016). </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>Subjects included were submitted to open bariatric surgery (with or without Rouxen-Y anastomosis) performed by the same team of surgeons and anesthetists. </plain></SENT>
<SENT sid="30" pm="."><plain>The inclusion criteria were American Society of Anesthesiologists II patients, aged 18–65 years scheduled for bariatric surgery. </plain></SENT>
<SENT sid="31" pm="."><plain>The exclusion criteria were refusal by the patient, cardiac or coronary disease, cardiac conduction abnormalities (QT interval duration of 450 ms or more), creatinine clearance lower than 60 mL/min, psychiatric mood or personality disorders, use of preoperative opioids or history of opioid misuse, and allergy to any of the study used drugs. </plain></SENT>
<SENT sid="32" pm="."><plain>Patients were allocated into two groups using computer-generated randomization, and demographic data were obtained. </plain></SENT>
<SENT sid="33" pm="."><plain>This manuscript adhered to the applicable Consolidated Standards of Reporting Trials guidelines. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>A nonblind medical assistant prepared the induction syringe and the opioid bolus solution for each patient. </plain></SENT>
<SENT sid="35" pm="."><plain>This assistant did not participate in any other part of data collection and patient information and allocation were kept in opaque sealed envelopes. </plain></SENT>
<SENT sid="36" pm="."><plain>All other assistants and health professionals involved were blinded, including preoperative, intraoperative and postoperative assessments. </plain></SENT>
<SENT sid="37" pm="."><plain>The induction syringe contained either methadone 0.15 mg/kg (group M) or fentanyl 6 µg/kg (group F), and each 5 mL bolus of the opioid bolus solution contained either methadone 0.05 mg/kg or fentany l 2 µg/kg. </plain></SENT>
<SENT sid="38" pm="."><plain>These doses have been demonstrated to be approximately equipotent21–23 and were diluted in a standardized format so that the final presentation was identical for both groups. </plain></SENT>
<SENT sid="39" pm="."><plain>The weight used to calculate the dosages was the ideal body weight (IBW) plus 20% calculated by Robinson’s formula,24 which is the most precise equation currently available to determine IBW.25 </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>Anesthesia was induced with i.v. midazolam (3 mg), propofol titrated until loss of consciousness, and cisatracurium (0.15 mg/kg total body weight). </plain></SENT>
<SENT sid="41" pm="."><plain>At induction, the patients received either methadone (0.15 mg/kg IBW+20%) or fentanyl (6 µg/kg IBW+20%). </plain></SENT>
<SENT sid="42" pm="."><plain>Maintenance of anesthesia consisted of sevoflurane 1.8%–2.2% and repeated boluses of cisatracurium for optimal surgical relaxation. </plain></SENT>
<SENT sid="43" pm="."><plain>Hypotension (decrease of 20% or more in initial blood pressure) was treated with boluses of metaraminol (0.5 mg) or ephedrine (5 mg) as clinically indicated. </plain></SENT>
<SENT sid="44" pm="."><plain>Hypertension (any value higher than initial blood pressure) was treated with boluses from the same induction opioid: either methadone (0.05 mg/ kg IBW+20%) or fentanyl (2 µg/kg IBW+20%) every 10 minutes if necessary. </plain></SENT>
<SENT sid="45" pm="."><plain>The opioid dilution was calculated so the anesthesiologist would always administer 5 mL of the opioid bolus solution if needed. </plain></SENT>
<SENT sid="46" pm="."><plain>Monitoring consisted of a five-lead electrocardiogram, pulse oximetry, noninvasive pressure monitoring, esophageal temperature, capnography, and gas analyzer. </plain></SENT>
<SENT sid="47" pm="."><plain>Adjuvants were used for an optimal multimodal analgesia and prevention of postoperative nausea and vomiting (PONV) at the beginning of the procedure (pantoprazole 40 mg, dexamethasone 4 mg, and ketoprofen 100 mg) and at its end (dipyrone 2 g, ondansetron 4 mg, and morphine 3 mg). </plain></SENT>
<SENT sid="48" pm="."><plain>A median upper abdominal incision was performed in all subjects, and all incisions were infiltrated with 20 mL of 0.375% ropivacaine by the surgeon. </plain></SENT>
<SENT sid="49" pm="."><plain>Prior to extubation, all patients received neostigmine 30 µg/kg and atropine 15 µg/kg. </plain></SENT>
<SENT sid="50" pm="."><plain>After extubation, if hypoventilation (respiratory rate less than 8) refractory to continuous positive airway pressure for 15 minutes occurred, naloxone 40 µg was administered. </plain></SENT>
</text></p><p><text><SENT sid="51" pm="."><plain>All patients used patient-controlled analgesia (PCA) (Hospira, Gemstar 7 Therapy®) for postoperative analgesia, installed in the operating room before transport to postanesthesia care unit (PACU). </plain></SENT>
<SENT sid="52" pm="."><plain>All PCA devices contained a 0.1% i.v. morphine solution, with a bolus of 2 mg, lockout interval of 5 minutes, and a 4 hour bolus limit of 30 mg. </plain></SENT>
<SENT sid="53" pm="."><plain>In addition, all patients received i.v. dipyrone 2 g every 6 hours. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>In PACU, patients were monitored with electrocardiogram, pulse oximetry, and noninvasive pressure monitoring; patients remained in PACU for 2 hours before discharged to the ward. </plain></SENT>
</text></p><p><text><SENT sid="55" pm="."><plain>Patients were assessed for pain using the visual analog pain score (VAS based on a 0–10 scale; 0 = no pain and 10 = worst pain possible) and side effects 10 minutes after extubation. </plain></SENT>
<SENT sid="56" pm="."><plain>The Richmond Agitation -Sedation Scale (RASS) was used to evaluate sedation, and the anesthesia awakening time was recorded. </plain></SENT>
<SENT sid="57" pm="."><plain>If the patient was complaining of pain, he or she was reminded that the PCA device was available for use. </plain></SENT>
<SENT sid="58" pm="."><plain>The PCA device was available for 48 hours after surgery. </plain></SENT>
<SENT sid="59" pm="."><plain>After 48 hours, boluses of morphine were prescribed as needed. </plain></SENT>
</text></p><p><text><SENT sid="60" pm="."><plain>The primary outcome was postoperative morphine consumption at 2, 6, 24, 48, and 72 hours after surgery. </plain></SENT>
<SENT sid="61" pm="."><plain>Secondary outcomes were pain score (VAS) at rest and while coughing, opioid-related side effects (nausea, vomiting, pruritus, urinary retention, and the necessity for supplementary oxygen), and sedation score (RASS) at 10 minutes after extubation and at 2, 6, 24, 48, and 72 hours postoperatively. </plain></SENT>
<SENT sid="62" pm="."><plain>Patient satisfaction with postoperative pain management was accessed at 24, 48, and 72 hours after surgery using a scale of 0= unsatisfied to 10= completely satisfied. </plain></SENT>
<SENT sid="63" pm="."><plain>Patients were also evaluated 3 months after surgery for the presence of spontaneous or evoked pain and the presence of dysesthesia or paresthesia in the incision area. </plain></SENT>
<SENT sid="64" pm="."><plain>Evoked pain was evaluated by manual palpation in and around the scar by the researcher. </plain></SENT>
<SENT sid="65" pm="."><plain>All care providers and research team members responsible for data collection were blinded to group assignment throughout the perioperative period. </plain></SENT>
</text></p><p><text><SENT sid="66" pm="."><plain>We used the primary outcome measure to estimate the sample size. </plain></SENT>
<SENT sid="67" pm="."><plain>The average morphine consumption for this procedure observed from 20 previous patient’s data was 28 mg in the first 24 hours after surgery. </plain></SENT>
<SENT sid="68" pm="."><plain>Following other study results, we estimated that a 40% reduction in morphine consumption would be considered as clinically meaningful. </plain></SENT>
<SENT sid="69" pm="."><plain>Fifty-six patients were needed to detect the 40% difference in the postoperative morphine consumption between the groups, with a SD of 6%, a test power of 80%, and level of significance of 5%. </plain></SENT>
</text></p><sec sec-type="methods"><title><text><SENT sid="70" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>Means were compared using the Student’s t-test for normally distributed data, and medians were compared with Kruskal–Wallis test if the data were not normally distributed. </plain></SENT>
<SENT sid="72" pm="."><plain>Fisher’s exact test was used to compare proportions. </plain></SENT>
<SENT sid="73" pm="."><plain>Two-way repeated-measures ANOVA was conducted with post hoc Bonferroni correction. </plain></SENT>
<SENT sid="74" pm="."><plain>Statistical tests were two-sided and performed at a significance level of 0.05. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results"><title><text><SENT sid="75" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="76" pm="."><plain>A total of 56 patients were scheduled to be included in the study. </plain></SENT>
<SENT sid="77" pm="."><plain>However, during the study, two clear different patterns of morphine consumption among patients were observed, with some patients consuming very low dosages of morphine while others consuming large amounts of morphine, and a preliminary analysis was performed by a nonblinded researcher. </plain></SENT>
<SENT sid="78" pm="."><plain>This analysis showed statistically relevant results and the recruitment stopped since one method of anesthesia was superior to the other, and patients that received fentanyl, group F, were using avoidable high doses of morphine. </plain></SENT>
<SENT sid="79" pm="."><plain>As a result, the analysis considered a total of 32 patients enrolled in the study, 16 in each group (Figure 1). </plain></SENT>
<SENT sid="80" pm="."><plain>Both groups were similar regarding demographic and clinical characteristics (Table 1). </plain></SENT>
<SENT sid="81" pm="."><plain>During anesthesia, both groups had similar intraoperative requirements regarding the opioid boluses needed, propofol dose at induction, the number of vasopressor boluses needed, intraoperative hydration, duration of anesthesia, and awakening time. </plain></SENT>
</text></p><p><text><SENT sid="82" pm="."><plain>As for the primary outcome, group F postoperative mean morphine consumption was 6.5 mg (95% CI 3.2–9.7) at 2 hours, 12.5 mg (95% CI 7.4–17.1) at 2–6 hours, 13.5 mg (95% CI 8.3–18.7) at 6–24 hours, 16.6 mg (95% CI 6.1–27.2) at 24–48 hours, and 4.2 (95% CI −0.3 to 8.6) at 48–72 hours. </plain></SENT>
<SENT sid="83" pm="."><plain>Group M postoperative mean morphine consumption was 0.1 mg (95% CI −0.1 to 0.4) at 2 hours, 0.9 mg (95% CI 0.2–1.6) at 2–6 hours, 3.1 mg (95% CI 1.9–4.4) at 6–24 hours, 2.1 mg (95% CI 0.8–3.4) at 24–48 hours, and 0.2 (95% CI −0.1 to 0.6) at 48–72 hours. </plain></SENT>
</text></p><p><text><SENT sid="84" pm="."><plain>When comparing both groups, the postoperative morphine consumption was significantly higher in group F than group M until 48 hours and at the moments or intervals of 2 hours (mean difference [MD] 6.4 mg; 95% CI 3.1–9.6; P&lt;0.001), 2–6 hours (MD 11.4 mg; 95% CI 6.5–16.2; P&lt;0.001), 6–24 hours (MD 10.4 mg; 95% CI 5.0–15.7; P&lt;0.001), and 24–48 hours (MD 14.5 mg; 95% CI 3.9–25.1; P=0.01). </plain></SENT>
<SENT sid="85" pm="."><plain>There was no difference in the opioid requirement in the 72-hour evaluation (MD 3.9 mg; 95% CI −0.5 to 8.4; P=0.08) (Figure 2). </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>Pain scores at rest were higher in group F at 2 hours (MD 3.1; 95% CI 1.9–3.2; P&lt;0.001), 6 hours (MD 2.4; 95% CI 1.5–3.3; P&lt;0.001), and 24 hours (MD 0.9; 95% CI 0.2–1.5; P=0.001) than group M. </plain></SENT>
<SENT sid="87" pm="."><plain>There was no statistical difference between the groups in the 48 hours (MD 0.2; 95% CI −0.1 to 0.6; P=0.13) and 72 hours (MD 0.1; 95% CI −0.1 to 0.4; P=0.3) postoperative scores. </plain></SENT>
<SENT sid="88" pm="."><plain>Pain scores at coughing were higher in group F at 2 hours (MD 5.3; 95% CI 4.1–6.5; P&lt;0.001), 6 hours (MD 3.4; 95% CI 2.4–4.5; P&lt;0.001), 24 hours (MD 2.6; 95% CI 1.3–3.9; P&lt;0.001), and 72 hours (MD 1.2; 95% CI 0.3–2.2; P=0.02), and no difference was observed at 48 hours between the two groups (MD 1.1; 95% CI −0.1 to 2.2; P=0.05) (Figure 3). </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>Ten minutes after extubation, RASS score was similar in both groups, but group F patients had higher pain scores (VAS: mean 1.37; range 0–7) than group M patients (VAS: 0 for all patients at this evaluation; P&lt;0.01; Kruskal–Wallis test). </plain></SENT>
<SENT sid="90" pm="."><plain>PONV was more common in group F than in group M at 10-minutes evaluation (37.5% vs 0%; P=0.02; Fisher’s exact test). </plain></SENT>
<SENT sid="91" pm="."><plain>The perioperative results are shown in Table 2. </plain></SENT>
<SENT sid="92" pm="."><plain>Opioid antagonist use was necessary in one patient of each group. </plain></SENT>
</text></p><p><text><SENT sid="93" pm="."><plain>Opioid-related side effects occurred more frequently in group F than in group M for nausea (75% vs 6.3%; P=0.001; Fisher’s exact test) and vomiting (31.3% vs 0%; P=0.001; Fisher’s exact test). </plain></SENT>
<SENT sid="94" pm="."><plain>The incidence of pruritus, need for supplementary oxygen, and RASS sedation scores were similar between the groups (Table 3). </plain></SENT>
<SENT sid="95" pm="."><plain>No patient had urinary retention; all patients scored 0 at RASS score at 24-, 48-, and 72-hour postoperative evaluations. </plain></SENT>
<SENT sid="96" pm="."><plain>No patients presented score higher than zero or lower than –2 at any of the postoperative evaluations. </plain></SENT>
<SENT sid="97" pm="."><plain>Also, no patient required supplementary oxygen for more than 6 hours postoperatively. </plain></SENT>
</text></p><p><text><SENT sid="98" pm="."><plain>The median patient satisfaction score was also lower for group F compared with group M at 24 hours (8.5, range 6–10 vs 10, range 9–10; P=0.004; Kruskal–Wallis test), 48 hours (9.0, range 6–10 vs 10, range 9–10; P=0.015; Kruskal–Wallis test), and 72 hours (9.5, range 7–10 vs 10, range 9–10; P=0.015; Kruskal–Wallis test) postoperatively. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>At the 3-month postoperative evaluation, both groups had similar pain at rest (P=0.6; Fisher’s exact test), pain while coughing (P=0.39; Fisher’s exact test), and dysesthesia symptoms (P=1.0; Fisher’s exact test). </plain></SENT>
<SENT sid="100" pm="."><plain>However, group F had more evoked pain at surgical scar palpation (56% vs 12.5%; P=0.02; Fisher’s exact test) than group M. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion"><title><text><SENT sid="101" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>Methadone in bariatric surgery showed to be safe and significantly reduced the postoperative opioid consumption, pain scores at rest and at movement, less opioid-related nausea and vomiting, and better patient satisfaction. </plain></SENT>
<SENT sid="103" pm="."><plain>Intraoperative methadone usage is relatively new in anesthesia and has not yet been extensively studied. </plain></SENT>
<SENT sid="104" pm="."><plain>This is the first trial to analyze intraoperative methadone use and postoperative pain management of morbidly obese patients. </plain></SENT>
</text></p><p><text><SENT sid="105" pm="."><plain>Our primary outcome was postoperative morphine consumption. </plain></SENT>
<SENT sid="106" pm="."><plain>Patients receiving fentanyl had a higher need for opioid usage in the postoperative period until 48 hours. </plain></SENT>
<SENT sid="107" pm="."><plain>This result was greater than the initially proposed 40% difference in morphine consumption. </plain></SENT>
<SENT sid="108" pm="."><plain>These findings are consistent with other trials studying methadone as the sole opioid in anesthesia for nonobese patients.13,15,17 Secondary outcomes as pain at rest and while coughing were higher in group F right after extubation and 24 hours after surgery. </plain></SENT>
<SENT sid="109" pm="."><plain>Lower postoperative pain scores for methadone use are also in accordance with other studies conducted in nonobese patients.13,15,17 </plain></SENT>
</text></p><p><text><SENT sid="110" pm="."><plain>Patients receiving fentanyl experienced more opioid-related side effects right after extubation and in the postoperative period until 72 hours. </plain></SENT>
<SENT sid="111" pm="."><plain>Patients on methadone presented less PONV. </plain></SENT>
<SENT sid="112" pm="."><plain>The incidences of pruritus, sedation, need for supplementary oxygen, and urinary retention were similar between groups. </plain></SENT>
<SENT sid="113" pm="."><plain>Patients were monitored with ECG for 2 hours at PACU, and no QT interval alterations were observed in both groups. </plain></SENT>
<SENT sid="114" pm="."><plain>Side effects with different opioids is still controversial in literature with some studies showing no difference in opioid-related side effects when comparing methadone with other opioids13,15,17,18 and one study that reported less of such side effects in the group that used methadone.14 </plain></SENT>
</text></p><p><text><SENT sid="115" pm="."><plain>Satisfaction with the postoperative pain management was higher among patients under methadone compared with those receiving fentanyl. </plain></SENT>
<SENT sid="116" pm="."><plain>We believe this is a consequence of the better analgesia provided by methadone, although the use of PCA is usually related to high scores of patient satisfaction since it easily alleviates pain when used. </plain></SENT>
<SENT sid="117" pm="."><plain>One study compared patient satisfaction with methadone versus fentanyl for cardiac surgery and found similar results.13 </plain></SENT>
</text></p><p><text><SENT sid="118" pm="."><plain>All patients in this study were submitted to the same protocol of general anesthesia and the same bariatric surgery technique. </plain></SENT>
<SENT sid="119" pm="."><plain>Intraoperative variables such as opioid, propofol and vasopressor boluses requirement, intraoperative hydration, duration of anesthesia, and awakening time were similar in both groups. </plain></SENT>
</text></p><p><text><SENT sid="120" pm="."><plain>The methadone favorable outcomes in postoperative opioid consumption and pain scores could be the result of a combination of factors. </plain></SENT>
<SENT sid="121" pm="."><plain>Methadone has a longer elimination half-life (13–50 hours)10,12,19 than fentanyl (8–10 hours),26 which may lead methadone to maintain an analgesic effect longer than fentanyl. </plain></SENT>
<SENT sid="122" pm="."><plain>In addition, fentanyl has an analgesic mechanism of action by acting as an MOR agonist; meanwhile methadone is MOR agonist but also antagonizes glutamate by blocking the NMDAr and inhibits reuptake of serotonin and noradrenaline.12 These other effects in pain transmission can enhance the analgesic potential of methadone when used in anesthesia compared with fentanyl. </plain></SENT>
<SENT sid="123" pm="."><plain>Probably the higher postoperative morphine consumption in the group has led to the higher incidence of PONV observed. </plain></SENT>
</text></p><p><text><SENT sid="124" pm="."><plain>This is the first study to establish an evaluation for postoperative chronic pain in this population (pain for a period of longer than 2 months)27 and pain 3 months after surgery. </plain></SENT>
<SENT sid="125" pm="."><plain>No statistical differences at the spontaneous pain and dysesthesia symptoms occurred between the two groups, but patients of group M presented lower evoked pain scores after the mechanical stimulus. </plain></SENT>
<SENT sid="126" pm="."><plain>There is consistent evidence that a better postoperative analgesia is related to less chronic pain after surgery.28 The most important limitation for these results is that the sample size was not calculated for chronic postoperative pain. </plain></SENT>
<SENT sid="127" pm="."><plain>So, more data on chronic pain after surgery with different interventions are necessary to understand the long-term impact of different multimodal analgesia methods. </plain></SENT>
<SENT sid="128" pm="."><plain>Despite the evidence that better postoperative analgesia is related to less chronic pain after surgery, no other methadone-related trial has yet conducted a long-term patient evaluation. </plain></SENT>
</text></p><p><text><SENT sid="129" pm="."><plain>Many practitioners would choose to avoid methadone for the target population of this study favoring short-acting opioids or no opioids because of the long and variable half-life of methadone in a population prone to sleep apnea and airway obstruction. </plain></SENT>
<SENT sid="130" pm="."><plain>The results suggested otherwise, that the use of methadone as sole opioid in bariatric surgery for morbidly obese patients was safe and significantly reduced the postoperative opioid consumption, leading to lower pain scores at rest and at movement, less opioid-related nausea and vomiting, and better patient satisfaction. </plain></SENT>
</text></p></sec></SecTag></body><back><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="131" pm="."><plain>Disclosure </plain></SENT>
</text></p><p><text><SENT sid="132" pm="."><plain>The authors report no conflicts of interest in this work. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="b1-jpr-11-2123"><text><SENT sid="133" pm="."><plain>1GerbershagenHJAduckathilSvan WijckAJPain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical proceduresAnesthesiology2013118493494423392233 </plain></SENT>
</text></ref><ref id="b2-jpr-11-2123"><text><SENT sid="134" pm="."><plain>2BeattieWSBadnerNHChoiPTMeta-analysis demonstrates statistically significant reduction in postoperative myocardial infarction with the use of thoracic epidural analgesiaAnesth Analg200397391992012933434 </plain></SENT>
</text></ref><ref id="b3-jpr-11-2123"><text><SENT sid="135" pm="."><plain>3PöppingDMEliaNMarretERemyCTramèrMRProtective effects of epidural analgesia on pulmonary complications after abdominal and thoracic surgery: a meta-analysisArch Surg200814310990999discussion 100018936379 </plain></SENT>
</text></ref><ref id="b4-jpr-11-2123"><text><SENT sid="136" pm="."><plain>4SinghNSidawyANDezeeKThe effects of the type of anesthesia on outcomes of lower extremity infrainguinal bypassJ Vasc Surg200644596497017000075 </plain></SENT>
</text></ref><ref id="b5-jpr-11-2123"><text><SENT sid="137" pm="."><plain>5KehletHJensenTSWoolfCJPersistent postsurgical pain: risk factors and preventionLancet200636795221618162516698416 </plain></SENT>
</text></ref><ref id="b6-jpr-11-2123"><text><SENT sid="138" pm="."><plain>6RodgersAWalkerNSchugSReduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trialsBMJ20003217275149311118174 </plain></SENT>
</text></ref><ref id="b7-jpr-11-2123"><text><SENT sid="139" pm="."><plain>7WuRHaggarFPorteNAssessing the feasibility of a randomised, double-blinded, placebo-controlled trial to investigate the role of intra-peritoneal ropivacaine in gastric bypass surgery: a protocolBMJ Open201448e005823 </plain></SENT>
</text></ref><ref id="b8-jpr-11-2123"><text><SENT sid="140" pm="."><plain>8AgarwalRHechtTELazoMCUmscheidCAVenous thromboembolism prophylaxis for patients undergoing bariatric surgery: a systematic reviewSurg Obes Relat Dis20106221322020176509 </plain></SENT>
</text></ref><ref id="b9-jpr-11-2123"><text><SENT sid="141" pm="."><plain>9FernandezAZDemariaEJTichanskyDSMultivariate analysis of risk factors for death following gastric bypass for treatment of morbid obesityAnn Surg2004239569870315082974 </plain></SENT>
</text></ref><ref id="b10-jpr-11-2123"><text><SENT sid="142" pm="."><plain>10ShaiovaLBergerABlindermanCDConsensus guideline on parenteral methadone use in pain and palliative carePalliat Support Care20086216517618501052 </plain></SENT>
</text></ref><ref id="b11-jpr-11-2123"><text><SENT sid="143" pm="."><plain>11ToombsJDKralLAMethadone treatment for pain statesAm Fam Physician20057171353135815832538 </plain></SENT>
</text></ref><ref id="b12-jpr-11-2123"><text><SENT sid="144" pm="."><plain>12KharaschEDIntraoperative methadone: rediscovery, reappraisal, and reinvigoration?Anesth Analg20111121131621173206 </plain></SENT>
</text></ref><ref id="b13-jpr-11-2123"><text><SENT sid="145" pm="."><plain>13MurphyGSSzokolJWAvramMJIntraoperative methadone for the prevention of postoperative painAnesthesiology201512251112112225837528 </plain></SENT>
</text></ref><ref id="b14-jpr-11-2123"><text><SENT sid="146" pm="."><plain>14UdelsmannAMacielFGServianDCMethadone and morphine during anesthesia induction for cardiac surgery. </plain></SENT>
<SENT sid="147" pm="."><plain>Repercussion in postoperative analgesia and prevalence of nausea and vomitingRev Bras Anestesiol201161669570122063370 </plain></SENT>
</text></ref><ref id="b15-jpr-11-2123"><text><SENT sid="148" pm="."><plain>15GottschalkADurieuxMENemergutECIntraoperative methadone improves postoperative pain control in patients undergoing complex spine surgeryAnesth Analg2011112121822320418538 </plain></SENT>
</text></ref><ref id="b16-jpr-11-2123"><text><SENT sid="149" pm="."><plain>16SimoniRFCangianiLMPereiraAMEfficacy of intraoperative methadone and clonidine in pain control in the immediate postoperative period after the use of remifentanilRev Bras Anestesiol200959442143019669016 </plain></SENT>
</text></ref><ref id="b17-jpr-11-2123"><text><SENT sid="150" pm="."><plain>17ChuiPTGinTA double-blind randomised trial comparing postoperative analgesia after perioperative loading doses of methadone or morphineAnaesth Intensive Care199220146511609941 </plain></SENT>
</text></ref><ref id="b18-jpr-11-2123"><text><SENT sid="151" pm="."><plain>18RichlinDMReubenSSPostoperative pain control with methadone following lower abdominal surgeryJ Clin Anesth1991321121162039637 </plain></SENT>
</text></ref><ref id="b19-jpr-11-2123"><text><SENT sid="152" pm="."><plain>19GourlayGKWillisRJLambertyJA double-blind comparison of the efficacy of methadone and morphine in postoperative pain controlAnesthesiology19866433223273954126 </plain></SENT>
</text></ref><ref id="b20-jpr-11-2123"><text><SENT sid="153" pm="."><plain>20BerdeCBBeyerJEBournakiMCLevinCRSethnaNFComparison of morphine and methadone for prevention of postoperative pain in 3- to 7-year-old childrenJ Pediatr19911191 Pt 11361412066846 </plain></SENT>
</text></ref><ref id="b21-jpr-11-2123"><text><SENT sid="154" pm="."><plain>21MercadanteSVillariPFerreraPCasuccioAGambaroVOpioid plasma concentrations during a switch from transdermal fentanyl to methadoneJ Palliat Med200710233834417472504 </plain></SENT>
</text></ref><ref id="b22-jpr-11-2123"><text><SENT sid="155" pm="."><plain>22MercadanteSFerreraPVillariPFrequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unitJ Pain Symptom Manage200937463264119345298 </plain></SENT>
</text></ref><ref id="b23-jpr-11-2123"><text><SENT sid="156" pm="."><plain>23MercadanteSBrueraEThe effect of age on opioid switching to methadone: a systematic reviewJ Palliat Med201215334735122352334 </plain></SENT>
</text></ref><ref id="b24-jpr-11-2123"><text><SENT sid="157" pm="."><plain>24RobinsonJDLupkiewiczSMPalenikLLopezLMArietMDetermination of ideal body weight for drug dosage calculationsAm J Hosp Pharm1983406101610196869387 </plain></SENT>
</text></ref><ref id="b25-jpr-11-2123"><text><SENT sid="158" pm="."><plain>25ShahBSucherKHollenbeckCBComparison of ideal body weight equations and published height-weight tables with body mass index tables for healthy adults in the United StatesNutr Clin Pract200621331231916772549 </plain></SENT>
</text></ref><ref id="b26-jpr-11-2123"><text><SENT sid="159" pm="."><plain>26LötschJPharmacokinetic-pharmacodynamic modeling of opioidsJ Pain Symptom Manage2005295 Suppl90103 </plain></SENT>
</text></ref><ref id="b27-jpr-11-2123"><text><SENT sid="160" pm="."><plain>27MacraeWADaviesHTOChronic postsurgical painCrombieIKEpidemiology of PainSeattleIASP Press1999125142 </plain></SENT>
</text></ref><ref id="b28-jpr-11-2123"><text><SENT sid="161" pm="."><plain>28de Brito CançadoTOOmaisMAshmawiHATorresMLChronic pain after cesarean section. </plain></SENT>
<SENT sid="162" pm="."><plain>Influence of anesthetic/surgical technique and postoperative analgesiaRev Bras Anestesiol201262676277423176985 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="f1-jpr-11-2123" position="float"><label>Figure 1</label><caption><p><text><SENT sid="163" pm="."><plain>CONSORT flow diagram. </plain></SENT>
</text></p><p><text><SENT sid="164" pm="."><plain>Abbreviation: CONSORT, Consolidated Standards of Reporting Trials. </plain></SENT>
</text></p></caption><graphic xlink:href="jpr-11-2123Fig1"/></fig></SecTag><SecTag type="FIG"><fig id="f2-jpr-11-2123" position="float"><label>Figure 2</label><caption><p><text><SENT sid="165" pm="."><plain>Postoperative morphine consumption (mg). </plain></SENT>
</text></p><p><text><SENT sid="166" pm="."><plain>Note: Data are mean (horizontal black straight segment), SD (boxplot: blue or green), and min and max (vertical black straight segment). </plain></SENT>
</text></p></caption><graphic xlink:href="jpr-11-2123Fig2"/></fig></SecTag><SecTag type="FIG"><fig id="f3-jpr-11-2123" position="float"><label>Figure 3</label><caption><p><text><SENT sid="167" pm="."><plain>Postoperative pain scores. </plain></SENT>
</text></p><p><text><SENT sid="168" pm="."><plain>Notes: (A) Pain scores while coughing. (B) Pain scores at rest. </plain></SENT>
<SENT sid="169" pm="."><plain>Data are mean (horizontal black straight segment), SD (boxplot: blue or green), and min and max (vertical black straight segment). </plain></SENT>
<SENT sid="170" pm="."><plain>When no patient reported pain (VAS= 0), only a small horizontal line is presented. </plain></SENT>
</text></p><p><text><SENT sid="171" pm="."><plain>Abbreviation: VAS, visual analog pain score. </plain></SENT>
</text></p></caption><graphic xlink:href="jpr-11-2123Fig3"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="t1-jpr-11-2123" position="float"><label>Table 1</label><caption><p><text><SENT sid="172" pm="."><plain>Patient characteristics </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>Characteristic </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>Group F </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>Group M </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>N </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>16 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>16 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>Sex (female) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>13 (81.2%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>11 (68.7%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>Age (years) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>43.2±11.0 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>46.2±13.3 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>Body mass index (kg/m2) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>44.2±9.4 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>47.6±5.7 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>ASA physical status </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>2 (100%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>2 (100%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>Smoking history </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>5 (31.2%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>7 (43.7)% </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>Drinking history </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>0 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>Hypertension </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>10 (62.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>12 (75%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>Resistant hypertensiona </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>5 (31.2%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>5 (31.2%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>IDDM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>2 (12.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>1 (6.2%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>NIDDM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>6 (37.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>6 (37.5%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>Thyroid disease </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>4 (25%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>2 (12.5%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>Dyslipidemia </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>5 (31.2%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>6 (37.5%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>Sleep apnea </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>2 (12.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>3 (18.7%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>Chronic musculoskeletal painb </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>6 (37.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>5 (31.2%) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>APFEL score </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>2.5 (2–3) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>2.3 (2–3) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-jpr-11-2123"><p><bold>Notes:</bold> Data are mean ± SD (normal distribution), median [min – max] (non-normal distribution), or number of patients (%).</p></fn><fn id="tfn2-jpr-11-2123"><label>a</label><p>Hypertension that remains uncontrolled (140/90 mmHg or higher) despite an optimal two-drug regimen that has had adequate time to work (at least 1 month since last drug or dosage adjustment).</p></fn><fn id="tfn3-jpr-11-2123"><label>b</label><p>Pain for more than 3 months. Reported sites of pain were knees (18% of n=32), lumbar (15% of n=32), and hip (9% of n=32). Drinking history= alcohol consumption of more than two drinks per day.</p></fn><fn id="tfn4-jpr-11-2123"><p><bold>Abbreviations:</bold> ASA, American Society of Anesthesiologists; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t2-jpr-11-2123" position="float"><label>Table 2</label><caption><p><text><SENT sid="224" pm="."><plain>Perioperative period: intraoperative and 10 minutes after extubation </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>Perioperative evaluations </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>Group F (n=16) </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>Group M (n=16) </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>P-value </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>Propofol requirement at induction (mg) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>130±39.8 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>141.9±54.7 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>0.49 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Volume of opioid boluses needed (mL)a </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>25.3±7.2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>21.6±6.8 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>0.14 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>Vasopressor bolus requirement (n)b </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>2 [0–12] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>0.5 [0–10] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>0.16 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>Intraoperative crystalloids (mL) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>1900±468.7 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>1887±332.4 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>0.93 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>Length of anesthesia (minutes) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>250.0 [220–310] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>250.0 [220–300] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>0.73 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Awakening time (minutes) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>16.4±3.0 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>16.8±4.1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>0.77 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>RASS 10 minutes after extubation (−5 to +4) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>−1.0 [−4 to 0] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>−1.1 [−3 to 0] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>0.23 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>Pain score 10 minutes after extubation (0–10) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>0 [0–7] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>0 [0–0] </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>&lt;0.01 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>Nausea 10 minutes after extubation (n) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>6 (37.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>0 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>0.02 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn5-jpr-11-2123"><p><bold>Notes:</bold> Variables with normal distribution are shown in each group as “mean ± SD” and “<italic>P</italic>-value” calculated with Student’s <italic>t</italic>-test. Variables with non-normal distribution are shown as “median [min–max]” and “<italic>P</italic>-value” calculated with Kruskal–Wallis test. Proportions are shown in each group as “n (%)” and “<italic>P</italic>-value” calculated with Fisher’s exact test.</p></fn><fn id="tfn6-jpr-11-2123"><label>a</label><p>Milliliters of a standardized opioid solution used for identical final aspect in both groups.</p></fn><fn id="tfn7-jpr-11-2123"><label>b</label><p>Standardized bolus of metaraminol or ephedrine.</p></fn><fn id="tfn8-jpr-11-2123"><p><bold>Abbreviation:</bold> RASS, Richmond Agitation -Sedation Scale.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t3-jpr-11-2123" position="float"><label>Table 3</label><caption><p><text><SENT sid="265" pm="."><plain>Postoperative opioid-related side effects – n (%) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>Side effects </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>Group F(n=16) </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>Group M(n=16) </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>P-valuea </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>Nausea </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>12 (75%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>1 (6.25%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>Vomiting </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>5 (31.25) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>0 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>Pruritus </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>4 (25%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>0 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>0.10 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>Need for supplementary oxygen 2 hours postoperatively </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>14 (87.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>11 (68.75%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>0.39 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>Need for supplementary oxygen 6 hours postoperatively </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>4 (25%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>2 (12.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>0.65 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>RASS lower than 0 at 2 hours </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>10 (62.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>5 (31.25) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>0.16 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>RASS lower than 0 at 6 hours </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>2 (12.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>2 (12.5%) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>1 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn9-jpr-11-2123"><label>a</label><p>Fisher’s exact test.</p></fn><fn id="tfn10-jpr-11-2123"><p><bold>Abbreviation:</bold> RASS, Richmond Sedation and Agitation Scale.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
